지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.7
- 수록면
- 1 - 12 (12page)
- DOI
- https://doi.org/10.3802/jgo.2024.35.e51
이용수
초록· 키워드
오류제보하기
Objective: The aim of this study was to determine the poly (ADP-ribose) polymeraseinhibitors (PARPis) response and outcome of ovarian cancer (OC) patients with BRCA1/2germline mutation and a histor y of breast cancer (BC).
Methods: Thirty-nine OC patients with BRCA1/2 germline mutation and a histor y of BC wereincluded. The clinicopathological characteristics, PARPis response and prognosis were analyzed.
Results: The median inter val from BC to OC diagnosis was 115.3 months (range=6.4–310.1).
A total of 38 patients (38/39, 97.4%) received platinum-based chemotherapy after surgicalremoval. The majority of these patients were reported to be platinum sensitive (92.1%, 35/38).
21 patients (53.8%) received PARPis treatment with 16 patients (76.2%) for maintenancetreatment and 5 patients (5/21, 23.8%) for salvage treatment. The median duration for PARPismaintenance and salvage treatment was 14.9 months (range=2.0–56.9) and 8.2 months(range=5.2–20.7), respectively. In the entire cohort, 5-year progression-free sur vival (PFS) andoverall sur vival (OS) rate was 33.1% and 78.9%, respectively. Patients with BRCA1 mutationhad a non-significantly worse 5-year PFS (28.6% vs. 45.8%, p=0.346) and 5-year OS (76.9% vs.
83.3%, p=0.426) than those with BRCA2 mutation. In patients with stage III–IV (n=31), firstline PARPis maintenance treatment associated with a non-significantly better PFS (medianPFS: NR vs. 22.4 months; 5-year PFS: 64.3% vs. 21.9%, p=0.096).
Conclusion: The current study shows that these patients may have a good response toplatinum-based chemotherapy and a favorable sur vival. And these patients can benefit fromPARPis treatment and will likely be suitable candidates for PARPis.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients
Cancer Research and Treatment
2017 .01
-
Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea
Cancer Research and Treatment
2020 .01
-
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
Obstetrics & Gynecology Science
2020 .01
-
Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea
Obstetrics & Gynecology Science
2019 .01
-
BRCA1 and BRCA2 Common Mutations in Iranian Breast Cancer Patients: a Meta Analysis
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
BRCA1/2 mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counseling
Journal of Gynecologic Oncology
2020 .01
-
Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study
Cancer Research and Treatment
2023 .01
-
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma
Cancer Research and Treatment
2015 .01
-
Self-Concept and Psychosocial Well-Being among Korean Women with BRCA1/2 Gene Mutations
Asian Oncology Nursing
2022 .03
-
The Novel Pathogenic Mutation c.849dupT in BRCA2 Contributes to the Nonsense-Mediated mRNA Decay of BRCA2 in Familial Breast Cancer
Journal of Breast Cancer
2018 .01
-
Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations
Journal of Breast Cancer
2018 .01
-
BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
Annals of Laboratory Medicine
2020 .01
-
Clinically Significant Unclassified Variants in BRCA1 and BRCA2 Genes among Korean Breast Cancer Patients
Cancer Research and Treatment
2017 .07
-
BRCA1/2 mutations, including large genomic rearrangements, among unselected ovarian cancer patients in Korea
Journal of Gynecologic Oncology
2018 .01
-
[Breast] Characteristics of Germline BRCA1 and BRCA2 Mutation Carriers and Non-Carriers among High-Risk Breast Cancer Patients
대한외과학회 학술대회 초록집
2022 .11
-
Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline BRCA1/2 Mutation Carriers: A Retrospective Cohort Study
Yonsei Medical Journal
2021 .12
-
Self-concept and Psychosocial Well-being in Women with BRCA1/2 Gene Mutation
성인간호학회 학술대회
2021 .08
-
Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Journal of Korean Medical Science
2021 .10
-
BRCA1-mutated ovarian cancer with skin metastasis: a case report
Obstetrics & Gynecology Science
2017 .01
-
Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening
Annals of Laboratory Medicine
2016 .01
최근 본 자료
댓글(0)
0